Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Cancer Therapies02:49

Cancer Therapies

10.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Artificial Intelligence-Powered Radiotherapy for Resource-Limited Settings: Advancing Cervical and Prostate Cancer Treatment Planning With the Radiation Planning Assistant.

JCO global oncology·2026
Same author

Association between author specialty and reported outcomes in nonrandomized comparisons of prostatectomy versus radiation.

JNCI cancer spectrum·2026
Same author

Clinical validation of tissue and liquid companion diagnostics for BRAF V600E detection in non-small cell lung cancers from the PHAROS study.

Cancer research communications·2026
Same author

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.

The Lancet. Oncology·2026
Same author

Development and Implementation of a Machine Learning Model for Prediction of Surgical Case Duration.

Joint Commission journal on quality and patient safety·2026

Related Experiment Video

Updated: Apr 15, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.6K

Immunotherapy in lung cancer.

Erminia Massarelli1, Vassiliki Papadimitrakopoulou1, James Welsh1

  • 11 Department of Thoracic Head and Neck Medical Oncology, 2 Department of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Translational Lung Cancer Research
|March 26, 2015
PubMed
Summary

Lung cancer survival remains poor, but immunotherapy, including checkpoint inhibitors targeting CTLA-4 and PD-1, shows promise. Further research is needed to optimize combinations with chemotherapy and radiation for non-small cell lung cancer and small cell lung cancer.

Keywords:
Lung cancercheckpoint inhibitorsimmunotherapynon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

18.6K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Metastatic lung cancer, including NSCLC and SCLC, has poor survival rates (<5% 5-year survival).
  • Molecular targeted therapies benefit a subset of NSCLC patients, but many lack actionable alterations for direct treatment.
  • Lung cancer is increasingly recognized as immunogenic, challenging previous beliefs.

Purpose of the Study:

  • To review recent advancements in lung cancer treatment, focusing on immunotherapy.
  • To highlight the potential of checkpoint inhibitors (CTLA-4, PD-1) in managing lung cancer.
  • To identify the need for further research into optimal combination therapies for NSCLC and SCLC.

Main Methods:

  • Review of recent clinical trial data for therapeutic vaccines and checkpoint inhibitors in lung cancer.
  • Analysis of ongoing Phase II and III trials combining chemotherapy and immunotherapy.
  • Evaluation of the efficacy and toxicity of CTLA-4 and PD-1 pathway inhibitors.

Main Results:

  • Checkpoint inhibitors targeting CTLA-4 and PD-1 demonstrate durable responses and manageable toxicity in lung cancer patients.
  • Therapeutic vaccines and immunotherapy challenge the notion of lung cancer being nonimmunogenic.
  • Several trials are investigating immunotherapy alone or combined with chemotherapy, with results anticipated soon.

Conclusions:

  • Immunotherapy, particularly checkpoint inhibitors, represents a significant advancement in lung cancer treatment.
  • Optimal combinations of immunotherapy with chemotherapy and radiation require further investigation for both NSCLC and SCLC.
  • Continued research is crucial to improve survival outcomes for patients with metastatic lung cancer.